The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

November 30, 2005

Conditions
Lung Cancer, Small CellSmall Cell Lung Cancer
Interventions
DRUG

topotecan

Trial Locations (31)

27609

GSK Investigational Site, Raleigh

32610

GSK Investigational Site, Gainesville

44106

GSK Investigational Site, Cleveland

44304

GSK Investigational Site, Akron

45236

GSK Investigational Site, Cincinnati

46260

GSK Investigational Site, Indianapolis

53215

GSK Investigational Site, Milwaukee

53792

GSK Investigational Site, Madison

54301

GSK Investigational Site, Green Bay

54401

GSK Investigational Site, Wausau

54601

GSK Investigational Site, La Crosse

55422

GSK Investigational Site, Robbinsdale

55455

GSK Investigational Site, Minneapolis

55805

GSK Investigational Site, Duluth

63110

GSK Investigational Site, Saint Louis

63141

GSK Investigational Site, St Louis

70112

GSK Investigational Site, New Orleans

70121

GSK Investigational Site, New Orleans

71103

GSK Investigational Site, Shreveport

72205

GSK Investigational Site, Little Rock

76104

GSK Investigational Site, Fort Worth

78229

GSK Investigational Site, San Antonio

87109

GSK Investigational Site, Albuquerque

90057

GSK Investigational Site, Los Angeles

92708

GSK Investigational Site, Fountain Valley

93309

GSK Investigational Site, Bakersfield

85013 - 4496

GSK Investigational Site, Phoenix

40536-0098

GSK Investigational Site, Lexington

04074

GSK Investigational Site, Scarborough

01107

GSK Investigational Site, Springfield

43614-5809

GSK Investigational Site, Toledo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY